Chengdu Xingrui Jingxuan Therapeutics Launches Phase I Trial for Prostate Cancer Radiopharmaceutical
I'm PortAI, I can summarize articles.
Chengdu Xingrui Jingxuan, a subsidiary of Fosun Pharma, has launched a Phase I clinical trial for SRT-007, a radiopharmaceutical aimed at treating prostate cancer. This announcement was made public through the Issuer Information Service of the Hong Kong Stock Exchange. The news is generated by AI and is for informational purposes only, not to be considered as financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments